Physician profile
Rian J Dickstein
NPI 1407026487
$143,772.41
in general payments reported to CMS, 2019-2025
70 companies · $35K in 2025
The $35K reported for 2025 was more than what 98% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,415 · 2020: $2,000 · 2021: $29K · 2022: $25K · 2023: $22K · 2024: $25K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $34K · Consulting Fee: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $7,797 · Travel and Lodging: $3,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $33,665.00 |
| Consulting Fee | $24,577.06 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,036.19 |
| Food and Beverage | $7,796.92 |
| Travel and Lodging | $3,214.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $45,103.31 | 2020-2025 | Jelmyto |
| E.R. Squibb & Sons, L.L.C. | $21,805.53 | 2019-2025 | Opdivo |
| Janssen Biotech, INC. | $17,622.42 | 2019-2025 | Carvykti, Rybrevant, Erleada |
| Sn Holdings, LLC | $16,560.20 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $12,515.91 | 2019-2025 | Adstiladrin |
| Olympus America INC. | $4,804.14 | 2019-2024 | Itind System |
| Pfizer INC. | $3,898.00 | 2019-2025 | |
| Verity Pharmaceuticals INC. | $2,518.55 | 2022-2025 | Tlando |
| Astrazeneca Pharmaceuticals LP | $2,185.08 | 2021-2025 | Imfinzi, Lynparza |
| Janssen Scientific Affairs, LLC | $2,172.50 | 2019-2025 | |
| Janssen Global Services, LLC | $2,020.00 | 2021 | |
| Gyrus Acmi, INC. | $842.60 | 2021-2025 | Uretero-Reno Videoscope |
| Civco Medical Instruments | $813.00 | 2021 | |
| Sumitomo Pharma America, INC. | $772.62 | 2023-2025 | Orgovyx, Gemtesa |
| Olympus Winter & Ibe Gmbh | $740.00 | 2024 | Single Use Repositionable Clip |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation | $740.00 | 2019-2021 | |
| Astellas Pharma US INC | $652.39 | 2019-2025 | Xtandi, Myrbetriq, Padcev |
| Progenics Pharmaceuticals, INC. | $563.85 | 2022-2025 | Pylarify |
| Abbvie INC. | $555.84 | 2019-2025 | Botox |
| Bayer Healthcare Pharmaceuticals INC. | $554.35 | 2019-2025 | |
| Boston Scientific Corporation | $472.00 | 2019-2025 | Spaceoar Vue System - 10ml, Rezum Generator |
| Merck Sharp & Dohme LLC | $428.85 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Coloplast Corp | $387.25 | 2019-2025 | Speedicath |
| Endo Pharmaceuticals INC. | $377.25 | 2019-2024 | Aveed, Xiaflex, Edex |
| Cipla USA INC. | $370.58 | 2021 | |
| Olympus Medical Systems Corporation | $370.00 | 2024 | |
| Immunitybio, INC. | $306.16 | 2024-2025 | |
| Teleflex LLC | $293.88 | 2022-2024 | Solesta |
| Dendreon Pharmaceuticals LLC | $275.35 | 2019-2025 | Provenge |
| Antares Pharma, INC. | $267.43 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Baxter Healthcare | $257.27 | 2019 | |
| Conmed Corporation | $236.49 | 2021 | |
| Urovant Sciences INC | $217.22 | 2021-2022 | |
| Myovant Sciences INC. | $187.18 | 2021-2022 | |
| Medtronic, INC. | $177.84 | 2022-2025 | Interstim |
| Tolmar Pharmaceuticals, INC. | $170.16 | 2019-2022 | |
| Histosonics, INC. | $150.00 | 2025 | |
| Endo USA, INC. | $146.12 | 2024-2025 | Xiaflex, Aveed |
| Novartis Pharmaceuticals Corporation | $129.01 | 2022-2025 | |
| Genzyme Corporation | $119.00 | 2019-2021 | |
| Tolmar, INC. | $100.16 | 2023-2024 | |
| Comsort, INC | $100.00 | 2019 | |
| Alnylam Pharmaceuticals INC. | $80.95 | 2021-2023 | Givlaari |
| Amgen INC. | $66.33 | 2019-2021 | |
| Caris Mpi, INC. | $57.28 | 2025 | Mi Cancer Seek |
| Accord Healthcare, INC. | $51.24 | 2023-2024 | |
| Ethicon US, LLC | $48.95 | 2019 | |
| Seagen INC. | $45.28 | 2022-2023 | Padcev |
| Myriad Genetic Laboratories, INC. | $44.28 | 2021-2022 | |
| 180 Medical, INC. | $43.89 | 2022-2023 | Cure Catheter |
| Aveo Pharmaceuticals, INC. | $30.59 | 2022-2023 | Fotivda |
| Blue Earth Diagnostics | $28.51 | 2020 | |
| Janssen Pharmaceuticals, INC | $27.55 | 2025 | Erleada |
| Tempus Ai, INC | $27.14 | 2024 | Xt Cdx |
| Exelixis INC. | $23.87 | 2023 | Cabometyx |
| Eisai INC. | $22.13 | 2019 | |
| Novo Nordisk INC | $20.97 | 2024 | Rivfloza |
| Karl Storz Endoscopy-America | $20.78 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $20.00 | 2025 | |
| Bioprotect Medical, INC. | $19.37 | 2025 | Bioprotect Balloon Implant System |
| Palette Life Sciences, INC. | $17.71 | 2022 | |
| Avadel Specialty Pharmaceuticals, LLC | $17.06 | 2019 | |
| Foundation Medicine, INC. | $16.99 | 2023 | Foundationone Cdx |
| Ambu INC. | $16.80 | 2022 | |
| Mission Pharmacal Company | $16.54 | 2022 | |
| Acerus Pharmaceuticals Corporation | $14.63 | 2021 | |
| Angiodynamics, INC. | $14.08 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$361,837.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rian Dickstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.